DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "OpportunityAnalyzer: Huntington's Disease - Opportunity Analysis and Forecast to 2024" drug pipelines to their offering.
Disease-Modifying Drugs Will Propel Huntington's Disease Market to $2.6 Billion by 2024
The Huntington's disease market will rise from around $252.6 million in 2014 to over $2.6 billion in 2024, representing a huge Compound Annual Growth Rate (CAGR) of 25.6%.
The report states that the main driver of this extensive growth, which will occur across the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan, will be the launch of efficacious disease-modifying drugs, Raptor's RP103 and Prana Biotechnology's PBT2.
Other drivers include the anticipated launch of enhanced symptomatic treatments, potential patient assistance programs which will reimburse expensive therapies, and an increase in the treatment rate of Huntington's disease patients.
Rebecca Robbins, MPharmacol, Analyst covering Neurology and Ophthalmology, explains: The scope for improvement in the Huntington's disease space is vast, with the greatest unmet need being the development of a disease-modifying drug that will slow or halt the progression of the disease, or prevent its development. In this way, the launch of such a drug would be a game-changer.
Currently, Raptor's RP103 is positioned to be the first potential disease-modifying drug to reach the market, giving it an important advantage over other disease-modifying drugs in the late-stage pipeline. Its main competitor will be Prana Biotechnology's PBT2, which is the only late-stage drug in the pipeline that is aiming to demonstrate an improvement in the cognitive deficits associated with the disease in clinical trials.
Of the 7MM, PBT2 and RP103 are expected to be launched in all but Japan by 2024, with Japan seeing the smallest market expansion of all the countries, rising from $0.6 million in 2014 to $1.5 million by 2024, at a CAGR of 10%. This is still very robust growth, however, and can be attributed primarily to the launch of Teva's SD-809 and pridopidine, both symptom-alleviating drugs. SD-809 is anticipated to launch in Japan in 2020, with sales in this market forecast to be worth $1.1 million in 2024.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
3.1 Etiology and Pathophysiology
3.2 Quality of Life
3.4 Diagnosis and Disease Monitoring
4.1 Disease Background
4.2 Risk Factors and Complications
4.3 Global Trends
4.4 Forecast Methodology
4.5 Epidemiological Forecast of HD (2014-2024)
5 Current Treatment Options
5.2 Product Profiles-Major Brands
6 Unmet Needs Assessment and Opportunity Analysis
6.2 Disease-Modifying Drugs
6.3 Efficacious Cognitive Enhancers
6.4 Improved Symptomatic Treatments
6.5 Identification of Disease Biomarker
6.6 Increased Knowledge of HD Pathogenesis
6.7 More Comprehensive Treatment Guidelines
6.8 Novel Formulations
7 R&D Strategies
7.2 Clinical Trial Design
8 Pipeline Assessment
8.2 Innovative Early-Stage Approaches
9 Pipeline Valuation Analysis
9.1 Clinical Benchmark of Key Pipeline Drugs
9.2 Commercial Benchmark of Key Pipeline Drugs
9.3 Competitive Assessment
9.4 Top-Line 10-Year Forecast
- Alliance Pharma
- Chiesi Group
- EUSA Pharma
- Prana Biotechnology
- Raptor Pharmaceutical
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/cnmhvb/opportunityanalyze